{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:33:27Z","timestamp":1772134407231,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/mp.2017.14","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T05:28:19Z","timestamp":1490074099000},"page":"384-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Identification of a novel, fast-acting GABAergic antidepressant"],"prefix":"10.1038","volume":"23","author":[{"given":"K M J","family":"McMurray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Ramaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Barkley-Levenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P S","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P K","family":"Elkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M K","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M L","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V H","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L A","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S C","family":"Dulawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A A","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,21]]},"reference":[{"key":"BFmp201714_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE . Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617\u2013627.","journal-title":"Arch Gen Psychiatry"},{"key":"BFmp201714_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","volume":"21","author":"RC Kessler","year":"2012","unstructured":"Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U . Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012; 21: 169\u2013184.","journal-title":"Int J Methods Psychiatr Res"},{"key":"BFmp201714_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrn1846","volume":"7","author":"O Berton","year":"2006","unstructured":"Berton O, Nestler EJ . New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137\u2013151.","journal-title":"Nat Rev Neurosci"},{"key":"BFmp201714_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/mp.2013.55","volume":"18","author":"K Martinowich","year":"2013","unstructured":"Martinowich K, Jimenez DV, Zarate Ca, Manji HK . Rapid antidepressant effects: moving right along. Mol Psychiatry 2013; 18: 856\u2013863.","journal-title":"Mol Psychiatry"},{"key":"BFmp201714_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/0306-3623(95)02054-3","volume":"27","author":"PJ Thornalley","year":"1996","unstructured":"Thornalley PJ . Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification\u2014a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996; 27: 565\u2013573.","journal-title":"Gen Pharmacol"},{"key":"BFmp201714_CR6","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1172\/JCI61319","volume":"122","author":"MG Distler","year":"2012","unstructured":"Distler MG, Plant LD, Sokoloff G, Hawk AJ, Aneas I, Wuenschell GE et al. Glyoxalase 1 increases anxiety by reducing GABA A receptor agonist methylglyoxal. J Clin Invest 2012; 122: 2306\u20132315.","journal-title":"J Clin Invest"},{"key":"BFmp201714_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00213-011-2574-z","volume":"221","author":"CS Benton","year":"2012","unstructured":"Benton CS, Miller BH, Skwerer S, Suzuki O, Schultz LE, Cameron MD et al. Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains. Psychopharmacology 2012; 221: 297\u2013315.","journal-title":"Psychopharmacology"},{"key":"BFmp201714_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuroscience.2013.05.031","volume":"247","author":"Y Yang","year":"2013","unstructured":"Yang Y, Yang D, Tang G, Zhou C, Cheng K, Zhou J et al. Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression. Neuroscience 2013; 247: 191\u2013200.","journal-title":"Neuroscience"},{"key":"BFmp201714_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.brainres.2013.09.033","volume":"1539","author":"G Patki","year":"2013","unstructured":"Patki G, Solanki N, Atrooz F, Allam F, Salim S . Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res 2013; 1539: 73\u201386.","journal-title":"Brain Res"},{"key":"BFmp201714_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nature04250","volume":"438","author":"I Hovatta","year":"2005","unstructured":"Hovatta I, Tennant RS, Helton R, Marr Ra, Singer O, Redwine JM et al. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 2005; 438: 662\u2013666.","journal-title":"Nature"},{"key":"BFmp201714_CR11","doi-asserted-by":"publisher","first-page":"e4649","DOI":"10.1371\/journal.pone.0004649","volume":"4","author":"R Williams","year":"2009","unstructured":"Williams R, Lim JE, Harr B, Wing C, Walters R, Distler MG et al. A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior. PLoS ONE 2009; 4: e4649.","journal-title":"PLoS ONE"},{"key":"BFmp201714_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1017\/S0033291706009135","volume":"37","author":"KS Kendler","year":"2007","unstructured":"Kendler KS, Gardner CO, Gatz M, Pedersen NL . The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol Med 2007; 37: 453\u2013462.","journal-title":"Psychol Med"},{"key":"BFmp201714_CR13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/mp.2010.65","volume":"16","author":"A Demirkan","year":"2011","unstructured":"Demirkan A, Penninx BWJH, Hek K, Wray NR, Amin N, Aulchenko YS et al. Genetic risk profiles for depression and anxiety in adult and elderly cohorts. Mol Psychiatry 2011; 16: 773\u2013783.","journal-title":"Mol Psychiatry"},{"key":"BFmp201714_CR14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0006-3223(02)01672-4","volume":"52","author":"JM Kent","year":"2002","unstructured":"Kent JM, Mathew SJ, Gorman JM . Molecular targets in the treatment of anxiety. Biol Psychiatry 2002; 52: 1008\u20131030.","journal-title":"Biol Psychiatry"},{"key":"BFmp201714_CR15","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1084\/jem.20081188","volume":"205","author":"A El-Osta","year":"2008","unstructured":"El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409\u20132417.","journal-title":"J Exp Med"},{"key":"BFmp201714_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/adb.12333","volume":"22","author":"KMJ McMurray","year":"2017","unstructured":"McMurray KMJ, Sidhu PS, Cook JM, Arnold LA, Palmer AA . Genetic and pharmacological manipulation of glyoxalase 1 regulates voluntary ethanol consumption in mice. Addict Biol 2017; 22: 381\u2013389.","journal-title":"Addict Biol"},{"key":"BFmp201714_CR17","doi-asserted-by":"publisher","first-page":"11691","DOI":"10.1073\/pnas.0712239105","volume":"105","author":"M Kawatani","year":"2008","unstructured":"Kawatani M, Okumura H, Honda K, Kanoh N, Muroi M, Dohmae N et al. The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I. Proc Natl Acad Sci U S A 2008; 105: 11691\u201311696.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFmp201714_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1021\/bc3003666","volume":"24","author":"N Kanoh","year":"2013","unstructured":"Kanoh N, Suzuki T, Kawatani M, Katou Y, Osada H, Iwabuchi Y . Dual structure-activity relationship of osteoclastogenesis inhibitor methyl gerfelin based on teg scanning. Bioconjug Chem 2013; 24: 44\u201352.","journal-title":"Bioconjug Chem"},{"key":"BFmp201714_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/mp.2013.144","volume":"19","author":"MD Opal","year":"2013","unstructured":"Opal MD, Klenotich SC, Morais M, Bessa J, Winkle J, Doukas D et al. Serotonin 2C receptor antagonists induce fast-onset antidepressant effects. Mol Psychiatry 2013; 19: 1106\u20131114.","journal-title":"Mol Psychiatry"},{"key":"BFmp201714_CR20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.npp.1300433","volume":"29","author":"SC Dulawa","year":"2004","unstructured":"Dulawa SC, Holick KA, Gundersen B, Hen R . Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004; 29: 1321\u20131330.","journal-title":"Neuropsychopharmacology"},{"key":"BFmp201714_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","volume":"29","author":"JF Cryan","year":"2005","unstructured":"Cryan JF, Mombereau C, Vassout A . The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571\u2013625.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFmp201714_CR22","first-page":"1","volume":"18","author":"J Jiao","year":"2012","unstructured":"Jiao J, Opal MD, Dulawa SC . Gestational environment programs adult depression-like behavior through methylation of the calcitonin gene-related peptide gene. Mol Psychiatry 2012; 18: 1\u20138.","journal-title":"Mol Psychiatry"},{"key":"BFmp201714_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd1825","volume":"4","author":"JF Cryan","year":"2005","unstructured":"Cryan JF, Holmes A . The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005; 4: 775\u2013790.","journal-title":"Nat Rev Drug Discov"},{"key":"BFmp201714_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tins.2011.11.004","volume":"35","author":"RS Duman","year":"2012","unstructured":"Duman RS, Voleti B . Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012; 35: 47\u201356.","journal-title":"Trends Neurosci"},{"key":"BFmp201714_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2013.00161","volume":"4","author":"Ca Browne","year":"2013","unstructured":"Browne Ca, Lucki I . Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013; 4: 1\u201318.","journal-title":"Front Pharmacol"},{"key":"BFmp201714_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00213-010-2140-0","volume":"213","author":"J Jiao","year":"2011","unstructured":"Jiao J, Nitzke AM, Doukas DG, Seiglie MP, Dulawa SC . Antidepressant response to chronic citalopram treatment in eight inbred mouse strains. Psychopharmacology 2011; 213: 509\u2013520.","journal-title":"Psychopharmacology"},{"key":"BFmp201714_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.expneurol.2006.09.008","volume":"204","author":"J Jarosik","year":"2007","unstructured":"Jarosik J, Legutko B, Unsicker K, von Bohlen Und, Halbach O . Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Exp Neurol 2007; 204: 20\u201328.","journal-title":"Exp Neurol"},{"key":"BFmp201714_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","volume":"23","author":"JF Cryan","year":"2002","unstructured":"Cryan JF, Markou A, Lucki I . Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238\u2013245.","journal-title":"Trends Pharmacol Sci"},{"key":"BFmp201714_CR29","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.neubiorev.2005.03.017","volume":"29","author":"SC Dulawa","year":"2005","unstructured":"Dulawa SC, Hen R . Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 2005; 29: 771\u2013783.","journal-title":"Neurosci Biobehav Rev"},{"key":"BFmp201714_CR30","unstructured":"Marcia JR, Stephanie CD . Identifying fast-onset antidepressants using Rodent models. Mol Psychiatry 2017 (in press)."},{"key":"BFmp201714_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00259-009-1292-9","volume":"37","author":"UMH Klumpers","year":"2010","unstructured":"Klumpers UMH, Veltman DJ, Drent ML, Boellaard R, Comans EFI, Meynen G et al. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging 2010; 37: 565\u2013574.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BFmp201714_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1176\/appi.ajp.159.4.663","volume":"159","author":"G Sanacora","year":"2002","unstructured":"Sanacora G, Mason GF, Rothman DL, Krystal JH . Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002; 159: 663\u2013665.","journal-title":"Am J Psychiatry"},{"key":"BFmp201714_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","volume":"62","author":"H M\u00f6hler","year":"2012","unstructured":"M\u00f6hler H . The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 2012; 62: 42\u201353.","journal-title":"Neuropharmacology"},{"key":"BFmp201714_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/da.20262","volume":"24","author":"AV Kalueff","year":"2007","unstructured":"Kalueff AV, Nutt DJ . Role of GABA in anxiety and depression. Depress Anxiety 2007; 24: 495\u2013517.","journal-title":"Depress Anxiety"},{"key":"BFmp201714_CR35","doi-asserted-by":"publisher","first-page":"23480","DOI":"10.3402\/ljm.v9.23480","volume":"9","author":"N Ahmed El zahaf","year":"2014","unstructured":"Ahmed El zahaf N, Salem Elhwuegi A . The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice. Libyan J Med 2014; 9: 23480.","journal-title":"Libyan J Med"},{"key":"BFmp201714_CR36","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/0006-3223(95)00049-7","volume":"38","author":"F Petty","year":"1995","unstructured":"Petty F, Trivedi MH, Fulton M, Rush AJ . Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 1995; 38: 578\u2013591.","journal-title":"Biol Psychiatry"},{"key":"BFmp201714_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0165-0173(01)00129-1","volume":"37","author":"A Guidotti","year":"2001","unstructured":"Guidotti A, Dong E, Matsumoto K, Pinna G, Rasmusson AM, Costa E . The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5alpha-dihydroprogesterone in psychiatric disorders. Brain Res - Brain Res Rev 2001; 37: 110\u2013115.","journal-title":"Brain Res - Brain Res Rev"},{"key":"BFmp201714_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0091-3057(00)00300-2","volume":"67","author":"RT Khisti","year":"2000","unstructured":"Khisti RT, Chopde CT, Jain SP . Antidepressant-like effect of the neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 2000; 67: 137\u2013143.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFmp201714_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/0269881106064203","volume":"21","author":"JF Rodriguez-Landa","year":"2006","unstructured":"Rodriguez-Landa JF, Contreras CM, Bernal-Morales B, Gutierrez-Garcia AG, Saavedra M . Allopregnanolone reduces immobility in the forced swimming test and increases the firing rate of lateral septal neurons through actions on the GABAA receptor in the rat. J Psychopharmacol 2006; 21: 76\u201384.","journal-title":"J Psychopharmacol"},{"key":"BFmp201714_CR40","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1038\/npp.2015.112","volume":"40","author":"J Fischell","year":"2015","unstructured":"Fischell J, Van Dyke AM, Kvarta MD, LeGates TA, Thompson SM . Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors. Neuropsychopharmacology 2015; 40: 2499\u20132509.","journal-title":"Neuropsychopharmacology"},{"key":"BFmp201714_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4088\/JCP.09m05131gry","volume":"72","author":"M Fava","year":"2011","unstructured":"Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 2011; 72: 473\u2013479.","journal-title":"J Clin Psychiatry"},{"key":"BFmp201714_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1463-1326.2006.00595.x","volume":"9","author":"N Ahmed","year":"2007","unstructured":"Ahmed N, Thornalley PJ . Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007; 9: 233\u2013245.","journal-title":"Diabetes Obes Metab"},{"key":"BFmp201714_CR43","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","volume":"414","author":"M Brownlee","year":"2001","unstructured":"Brownlee M . Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813\u2013820.","journal-title":"Nature"},{"key":"BFmp201714_CR44","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1042\/BST20140027","volume":"42","author":"KMJ McMurray","year":"2014","unstructured":"McMurray KMJ, Distler MG, Sidhu PS, Cook JM, Arnold La, Palmer AA et al. Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development. Biochem Soc Trans 2014; 42: 461\u2013467.","journal-title":"Biochem Soc Trans"},{"key":"BFmp201714_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fgene.2012.00250","volume":"3","author":"MG Distler","year":"2012","unstructured":"Distler MG, Palmer AA . Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights. Front Genet 2012; 3: 250.","journal-title":"Front Genet"},{"key":"BFmp201714_CR46","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.biopsych.2006.02.013","volume":"59","author":"RS Duman","year":"2006","unstructured":"Duman RS, Monteggia LM . A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116\u20131127.","journal-title":"Biol Psychiatry"},{"key":"BFmp201714_CR47","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jad.2014.11.044","volume":"174","author":"M Polyakova","year":"2015","unstructured":"Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML . BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2015; 174: 432\u2013440.","journal-title":"J Affect Disord"},{"key":"BFmp201714_CR48","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1523\/JNEUROSCI.15-11-07539.1995","volume":"15","author":"M Nibuya","year":"1995","unstructured":"Nibuya M, Morinobu S, Duman RS . Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539\u20137547.","journal-title":"J Neurosci"},{"key":"BFmp201714_CR49","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.eurpsy.2013.10.005","volume":"29","author":"W Zhou","year":"2014","unstructured":"Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ . Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry 2014; 29: 419\u2013423.","journal-title":"Eur Psychiatry"},{"key":"BFmp201714_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91\u201395.","journal-title":"Nature"},{"key":"BFmp201714_CR51","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1017\/S1461145711000782","volume":"15","author":"J Pascual-Brazo","year":"2012","unstructured":"Pascual-Brazo J, Castro E, D\u00edaz A, Valdiz\u00e1n EM, Pilar-Cu\u00e9llar F, Vidal R et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT4 receptor agonist RS67333. Int J Neuropsychopharmacol 2012; 15: 631\u2013643.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFmp201714_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.biocel.2007.07.019","volume":"40","author":"S Di Loreto","year":"2008","unstructured":"Di Loreto S, Zimmitti V, Sebastiani P, Cervelli C, Falone S, Amicarelli F . Methylglyoxal causes strong weakening of detoxifying capacity and apoptotic cell death in rat hippocampal neurons. Int J Biochem Cell Biol 2008; 40: 245\u2013257.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFmp201714_CR53","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/epi.12121","volume":"54","author":"MG Distler","year":"2013","unstructured":"Distler MG, Gorfinkle N, Papale LA, Wuenschell GE, Termini J, Escayg A et al. Glyoxalase 1 and its substrate methylglyoxal are novel regulators of seizure susceptibility. Epilepsia 2013; 54: 649\u2013657.","journal-title":"Epilepsia"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/mp201714.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/mp201714","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/mp.2017.14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/mp201714.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:17:09Z","timestamp":1684419429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp201714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFmp201714"],"URL":"https:\/\/doi.org\/10.1038\/mp.2017.14","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727434600.793533385","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]},"assertion":[{"value":"21 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs Palmer and McMurray have applied for a patent-related manipulation of GLO1 to treat various neurological and psychiatric disorders. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}